loncastuximab tesirine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
human origin 5452 1879918-31-6

Description:

MoleculeDescription

Molfile

Synonyms:

  • loncastuximab tesirine
  • loncastuximab tesirine-lpyl
  • zynlonta
  • ADCT-402
Loncastuximab tesirine-lpyl is an antibody-drug conjugate (ADC) targeting CD19. The monoclonal IgG1 kappa antibody component binds to human CD19, a transmembrane protein expressed on the surface of cells of B-lineage origin. The small molecule component is SG3199, a PBD dimer and alkylating agent. Upon binding to CD19, loncastuximab tesirine-lpyl is internalized followed by release of SG3199 via proteolytic cleavage. The released SG3199 binds to the DNA minor groove and forms highly cytotoxic DNA interstrand crosslinks, subsequently inducing cell death. Loncastuximab tesirine-lpyl had anticancer activity in animal models of lymphoma.
  • Molecular weight:
  • Formula:
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

None

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

None

Approvals:

DateAgencyCompanyOrphan
April 23, 2021 FDA ADC Therapeutics SA
Dec. 20, 2022 EMA Swedish Orphan Biovitrum AB

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L01FX22 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
Other monoclonal antibodies and antibody drug conjugates
MeSH PA D000074322 Antineoplastic Agents, Immunological
MeSH PA D000970 Antineoplastic Agents
CHEBI has role CHEBI:35610 antineoplastic agent

Related Drugs by ATC class:

L01FX Other monoclonal antibodies and antibody drug conjugates 29 drugs
amivantamabbelantamab mafodotinblinatumomabbrentuximab vedotincatumaxomabdatopotamab deruxtecanelotuzumabelranatamabenfortumab vedotinepcoritamabgemtuzumab ozogamicinglofitamab show all 29 →

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Diffuse large B-cell lymphoma indication 46732000
Relapsed or refractory large B-cell lymphoma indication 109979007




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
B-lymphocyte antigen CD19 Surface antigen ANTIBODY BINDING UNKNOWN DRUG LABEL

External reference:

IDSource
D11338 KEGG_DRUG
7K5O7P6QIU UNII
C5203804 UMLSCUI
CHEBI:757226 CHEBI
CHEMBL4297778 ChEMBL_ID
DB16222 DRUGBANK_ID
CHEMBL4297238 ChEMBL_ID
10586 INN_ID
C000710749 MESH_SUPPLEMENTAL_RECORD_UI
11521 IUPHAR_LIGAND_ID
1157143009 SNOMEDCT_US
1157144003 SNOMEDCT_US
4040429 VANDF
345725 MMSL
39485 MMSL
d09733 MMSL
018707 NDDF
2540964 RXNORM

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
ZYNLONTA HUMAN PRESCRIPTION DRUG LABEL 1 79952-110 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 10 mg INTRAVENOUS BLA 33 sections
ZYNLONTA HUMAN PRESCRIPTION DRUG LABEL 1 79952-110 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 10 mg INTRAVENOUS BLA 33 sections